Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | CRHBP | P24387 | 2/20 | 0.46 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.46 |
| ▸ | ELANE | P08246 | 3/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.46 |
| ▸ | PPARG | P37231 | 2/20 | 0.44 |
| ▸ | PPARA | Q07869 | 2/20 | 0.44 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28584562 | 0.91 | CYP1A2 (0.65) | CYP1A2GAACYP2C9PKMCYP2C19 | |
| SCHEMBL655457 | 0.91 | CYP1A2 (0.65) | CYP1A2GAACYP2C9PKMCYP2C19 | |
| SCHEMBL12852977 | 0.86 | CYP1A2 (0.69) | CYP1A2GAACYP2C9PKMCYP2C19 | |
| SCHEMBL11749709 | 0.86 | CYP1A2 (0.59) | CYP1A2GAACYP2C9PKMCYP2C19 | |
| SCHEMBL11116546 | 0.84 | PARP10 (0.65) | SMN1; SMN2KMT2AALDH1A1LMNAHPGD | |
| SCHEMBL8638497 | 0.83 | HPGD (0.59) | CYP1A2GAACYP2C9PKMCYP2C19 | |
| SCHEMBL8638490 | 0.83 | HPGD (0.59) | CYP1A2GAACYP2C9PKMCYP2C19 | |
| SCHEMBL4262556 | 0.82 | CYP1A2 (0.77) | CYP1A2GAACYP2C9PKMCYP2C19 | |
| SCHEMBL2234094 | 0.80 | KMT2A (0.71) | CYP1A2GAACYP2C9PKMCYP2C19 | |
| SCHEMBL943227 | 0.79 | GAA (0.62) | CYP1A2GAACYP2C9PKMCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120028927-A1 | Novel Triazene Compounds For The Treatment Of Cancer | TRIN THERAPEUTICS GMBH (DE) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028927-A1 | Novel Triazene Compounds For The Treatment Of Cancer | KRAS, TP53, VHL | CYP1A2 3497/4885GAA 490/4885CYP2C9 3148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.